(15331321), C. K. L., (15331324), A. R. A., (15331327), T. H., (15331330), J. Z., (15036467), D. K., (15331333), R. A. S., . . . (11678896), Y. W. (2025). Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis.
Cita Chicago Style (17a ed.)(15331321), Chong Kin Liam, et al. Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis. 2025.
Cita MLA (9a ed.)(15331321), Chong Kin Liam, et al. Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis. 2025.